(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 May 2006 (11.05.2006)

PCT

(10) International Publication Number
WO 2006/048295 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61P 25/00* (2006.01)
A61K 39/385 (2006.01) *C07K 16/00* (2006.01)
A61P 25/28 (2006.01) *A61K 47/48* (2006.01)

(21) International Application Number:
PCT/EP2005/011788

(22) International Filing Date:
3 November 2005 (03.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0424563.5 5 November 2004 (05.11.2004) GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-123O Vienna (AT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GRAF, Ana** [CH/CH]; Schaeferstrasse 12A, CH-4125 Riehen (CH). **STAUFENBIEL, Matthias** [DE/DE]; Müllerweg 7, 79541 Lörrach (DE). **BLÄTTLER, Thomas** [CH/CH]; Hof Wisler 5, CH-4461 Böckten (CH). **PAGANETTI, Paolo** [CH/CH]; Schöllenenstrasse 27, ch-4054 Basel (CH).

(74) Agent: **LEON, Susanna**; Novartis AG, Lichtstrasse 35, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** COMPOSITION COMPRISING VLP AND AMYLOID-BETA PEPTIDE

(57) **Abstract:** The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the Aß-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.

WO 2006/048295 A1